Cong-li Zhang

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.

Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.

Journal: Leukemia & lymphoma

Published: November 20, 2020

Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients.

Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients.

Journal: Annals of hematology

Published: December 28, 2019

Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival.

Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: October 23, 2019

Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement.

Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement.

Journal: Leukemia research

Published: July 24, 2019

Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.

Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: May 11, 2019

Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.

Clinical presentation and prognosis of immunoglobulin light-chain amyloidosis with high percentage of bone marrow plasma cells.

Journal: Leukemia research

Published: January 24, 2019

Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.

Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.

Journal: Annals of hematology

Published: June 05, 2018

At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.

At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.

Journal: Annals of hematology

Published: April 17, 2017

Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.

Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.

Journal: Annals of hematology

Published: January 13, 2017

Selection of Biopsy Site for Patients with Systematic Amyloidosis.

Selection of Biopsy Site for Patients with Systematic Amyloidosis.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: January 10, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026